BACK
portfolio company

Berkeley Lights

sector
Drug Discovery & Therapeutics
 •
Diagnostics & Imaging
 •
status
IPO
Initial Investment
2014
location
USA
Optofluidic platform for single-cell biology and biologics discovery.
company overview

Berkeley Lights pioneered optofluidic single-cell biology with its Beacon platform, used by biopharma to accelerate antibody discovery, cell line development, and cell therapy research. The company went public on Nasdaq in July 2020, merged with IsoPlexis to form PhenomeX in 2023, and was acquired by Bruker Corporation later that year.

social media
Related NEWS